TY - JOUR
T1 - Cofactor mimics as selective inhibitors of NAD-dependent inosine monophospate dehydrogenase (IMPDH) - The major therapeutic target
AU - Pankiewicz, Krzysztof W.
AU - Patterson, Steven E.
AU - Black, Paul L.
AU - Jayaram, Hiremagalur N.
AU - Risal, Dipesh
AU - Goldstein, Barry M.
AU - Stuyver, Lieven J.
AU - Schinazi, Raymond F.
PY - 2004/4
Y1 - 2004/4
N2 - IMP dehydrogenase, the key enzyme in de novo synthesis of purine nucleotides, is an important therapeutic target. Three inhibitors of IMP dehydrogenase reached the market; ribavirin (Rebetol) a broad-spectrum antiviral agent, which in combination with interferon-α is now used for treatment of hepatitis C virus infections, mizoribine (Bredinin and mycophenolic mofetil (CellCept) have been introduced as immunosuppressants. Numerous novel inhibitors are under development. This review describes recent progress in the development of new drugs based on inhibition of IMP dehydrogenase.
AB - IMP dehydrogenase, the key enzyme in de novo synthesis of purine nucleotides, is an important therapeutic target. Three inhibitors of IMP dehydrogenase reached the market; ribavirin (Rebetol) a broad-spectrum antiviral agent, which in combination with interferon-α is now used for treatment of hepatitis C virus infections, mizoribine (Bredinin and mycophenolic mofetil (CellCept) have been introduced as immunosuppressants. Numerous novel inhibitors are under development. This review describes recent progress in the development of new drugs based on inhibition of IMP dehydrogenase.
UR - http://www.scopus.com/inward/record.url?scp=1842431902&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1842431902&partnerID=8YFLogxK
U2 - 10.2174/0929867043455648
DO - 10.2174/0929867043455648
M3 - Review article
C2 - 15083807
AN - SCOPUS:1842431902
SN - 0929-8673
VL - 11
SP - 887
EP - 900
JO - Current medicinal chemistry
JF - Current medicinal chemistry
IS - 7
ER -
